Blueprint Medicines Corp (BPMC)

$90.73

-1.53

(-1.66%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Blueprint Medicines Corp

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 56.56M → 71.95M (in $), with an average increase of 21.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -133.71M → -110.91M (in $), with an average increase of 20.6% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 249.7%

Performance

  • $88.83
    $91.46
    $90.73
    downward going graph

    2.09%

    Downside

    Day's Volatility :2.88%

    Upside

    0.8%

    downward going graph
  • $43.89
    $101.00
    $90.73
    downward going graph

    51.63%

    Downside

    52 Weeks Volatility :56.54%

    Upside

    10.17%

    downward going graph

Returns

PeriodBlueprint Medicines CorpSector (Health Care)Index (Russel 2000)
3 Months
11.24%
0.5%
0.0%
6 Months
64.31%
11.7%
0.0%
1 Year
85.09%
6.2%
2.2%
3 Years
-10.17%
13.5%
-23.0%

Highlights

Market Capitalization
5.5B
Book Value
$2.14
Earnings Per Share (EPS)
-8.37
PEG Ratio
0.0
Wall Street Target Price
97.38
Profit Margin
-203.3%
Operating Margin TTM
-146.07%
Return On Assets TTM
-25.34%
Return On Equity TTM
-157.14%
Revenue TTM
249.4M
Revenue Per Share TTM
4.12
Quarterly Revenue Growth YOY
85.5%
Gross Profit TTM
177.3M
EBITDA
-474.6M
Diluted Eps TTM
-8.37
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.55
EPS Estimate Next Year
-2.78
EPS Estimate Current Quarter
-2.04
EPS Estimate Next Quarter
-1.75

Analyst Recommendation

Buy
    76%Buy
    16%Hold
    8%Sell
Based on 25 Wall street analysts offering stock ratings for Blueprint Medicines Corp(by analysts ranked 0 to 5 stars)
Based on 25 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
18
18
Hold
4
5
5
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 7.33%

Current $90.73
Target $97.38

Company Financials

FY18Y/Y Change
Revenue
44.5M
↑ 107.79%
Net Income
-236.6M
↑ 59.76%
Net Profit Margin
-531.53%
↑ 159.77%
FY19Y/Y Change
Revenue
66.5M
↑ 49.39%
Net Income
-328.7M
↑ 38.9%
Net Profit Margin
-494.2%
↑ 37.33%
FY20Y/Y Change
Revenue
793.7M
↑ 1093.37%
Net Income
313.9M
↓ 195.49%
Net Profit Margin
39.54%
↑ 533.74%
FY21Y/Y Change
Revenue
180.1M
↓ 77.31%
Net Income
-644.1M
↓ 305.2%
Net Profit Margin
-357.67%
↓ 397.21%
FY22Y/Y Change
Revenue
204.0M
↑ 13.3%
Net Income
-557.5M
↓ 13.44%
Net Profit Margin
-273.24%
↑ 84.43%
FY23Y/Y Change
Revenue
249.4M
↑ 22.22%
Net Income
-507.0M
↓ 9.06%
Net Profit Margin
-203.3%
↑ 69.94%
Q3 FY22Q/Q Change
Revenue
66.0M
↑ 80.53%
Net Income
-133.2M
↓ 16.62%
Net Profit Margin
-201.83%
↑ 235.17%
Q4 FY22Q/Q Change
Revenue
38.8M
↓ 41.22%
Net Income
-158.6M
↑ 19.13%
Net Profit Margin
-409.06%
↓ 207.23%
Q1 FY23Q/Q Change
Revenue
63.3M
↑ 63.19%
Net Income
-129.6M
↓ 18.33%
Net Profit Margin
-204.72%
↑ 204.34%
Q2 FY23Q/Q Change
Revenue
57.6M
↓ 9.03%
Net Income
-132.8M
↑ 2.5%
Net Profit Margin
-230.66%
↓ 25.94%
Q3 FY23Q/Q Change
Revenue
56.6M
↓ 1.74%
Net Income
-133.7M
↑ 0.69%
Net Profit Margin
-236.38%
↓ 5.72%
Q4 FY23Q/Q Change
Revenue
72.0M
↑ 27.21%
Net Income
-110.9M
↓ 17.05%
Net Profit Margin
-154.14%
↑ 82.24%
FY18Y/Y Change
Total Assets
540.1M
↓ 24.54%
Total Liabilities
121.1M
↑ 31.98%
FY19Y/Y Change
Total Assets
707.7M
↑ 31.02%
Total Liabilities
243.3M
↑ 100.91%
FY20Y/Y Change
Total Assets
1.7B
↑ 142.82%
Total Liabilities
248.3M
↑ 2.04%
FY21Y/Y Change
Total Assets
1.3B
↓ 27.13%
Total Liabilities
281.5M
↑ 13.36%
FY22Y/Y Change
Total Assets
1.3B
↑ 7.8%
Total Liabilities
835.2M
↑ 196.72%
FY23Y/Y Change
Total Assets
1.0B
↓ 22.27%
Total Liabilities
918.6M
↑ 9.99%
Q3 FY22Q/Q Change
Total Assets
1.5B
↑ 22.3%
Total Liabilities
818.1M
↑ 83.97%
Q4 FY22Q/Q Change
Total Assets
1.3B
↓ 7.44%
Total Liabilities
835.2M
↑ 2.1%
Q1 FY23Q/Q Change
Total Assets
1.2B
↓ 9.6%
Total Liabilities
806.1M
↓ 3.49%
Q2 FY23Q/Q Change
Total Assets
1.1B
↓ 9.34%
Total Liabilities
795.3M
↓ 1.33%
Q3 FY23Q/Q Change
Total Assets
1.1B
↓ 0.1%
Total Liabilities
902.7M
↑ 13.5%
Q4 FY23Q/Q Change
Total Assets
1.0B
↓ 5.07%
Total Liabilities
918.6M
↑ 1.77%
FY18Y/Y Change
Operating Cash Flow
-175.0M
↑ 46.01%
Investing Cash Flow
-161.1M
↑ 112.38%
Financing Cash Flow
4.5M
↓ 99.18%
FY19Y/Y Change
Operating Cash Flow
-278.0M
↑ 58.86%
Investing Cash Flow
-16.5M
↓ 89.78%
Financing Cash Flow
340.6M
↑ 7547.91%
FY20Y/Y Change
Operating Cash Flow
387.0M
↓ 239.21%
Investing Cash Flow
-434.2M
↑ 2537.25%
Financing Cash Flow
617.8M
↑ 81.35%
FY21Y/Y Change
Operating Cash Flow
-298.7M
↓ 177.16%
Investing Cash Flow
-225.9M
↓ 47.99%
Financing Cash Flow
50.7M
↓ 91.79%
FY22Y/Y Change
Operating Cash Flow
-502.3M
↑ 68.18%
Investing Cash Flow
-149.5M
↓ 33.79%
Financing Cash Flow
561.8M
↑ 1007.76%
Q3 FY22Q/Q Change
Operating Cash Flow
-129.9M
↑ 9.84%
Investing Cash Flow
-132.2M
↓ 271.58%
Financing Cash Flow
380.6M
↑ 114.4%
Q4 FY22Q/Q Change
Operating Cash Flow
-121.4M
↓ 6.53%
Investing Cash Flow
-53.3M
↓ 59.71%
Financing Cash Flow
2.5M
↓ 99.35%
Q1 FY23Q/Q Change
Operating Cash Flow
-123.0M
↑ 1.28%
Investing Cash Flow
172.8M
↓ 424.29%
Financing Cash Flow
5.3M
↑ 112.69%
Q2 FY23Q/Q Change
Operating Cash Flow
-130.5M
↑ 6.11%
Investing Cash Flow
32.1M
↓ 81.44%
Financing Cash Flow
5.3M
↑ 0.0%
Q3 FY23Q/Q Change
Operating Cash Flow
-104.5M
↓ 19.92%
Investing Cash Flow
-9.6M
↓ 129.89%
Financing Cash Flow
98.4M
↑ 1757.29%

Technicals Summary

Sell

Neutral

Buy

Blueprint Medicines Corp is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Blueprint Medicines Corp
Blueprint Medicines Corp
1.18%
64.31%
85.09%
-10.17%
18.05%
Moderna, Inc.
Moderna, Inc.
-1.15%
39.75%
-18.77%
-40.22%
304.34%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.56%
12.46%
14.48%
77.72%
159.17%
Novo Nordisk A/s
Novo Nordisk A/s
-2.8%
32.13%
52.48%
239.51%
414.16%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.96%
10.08%
23.01%
83.3%
130.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Blueprint Medicines Corp
Blueprint Medicines Corp
NA
NA
0.0
-5.55
-1.57
-0.25
NA
2.14
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Blueprint Medicines Corp
Blueprint Medicines Corp
Buy
$5.5B
18.05%
NA
-203.3%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
304.34%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
159.17%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
414.16%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
130.08%
28.81
36.68%

Institutional Holdings

  • BlackRock Inc

    10.75%

  • Vanguard Group Inc

    9.99%

  • T. Rowe Price Associates, Inc.

    8.87%

  • FMR Inc

    7.10%

  • Wellington Management Company LLP

    6.98%

  • Rock Springs Capital Management LP

    4.71%

Corporate Announcements

  • Blueprint Medicines Corp Earnings

    Blueprint Medicines Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development

Organization
Blueprint Medicines Corp
Employees
655
CEO
Ms. Kathryn Haviland
Industry
Health Technology

Discover More

FAQs